Partnerships - EnVivo
Nicotinic Alpha7 Program - Mitsubishi-Tanabe Pharmaceuticals (MTPC) EnVivo Pharmaceuticals has an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries.
HDAC Program - MethylGene, Inc.
EnVivo has an exclusive worldwide license from MethylGene, Inc.(Montreal, Québec; TSX:MYG, www.methylgene.com), to operate in the field of HDAC inhibitors for neurodegenerative diseases.
Nicotinic Alpha7 Program - Bayer Healthcare (BHC)
EnVivo has an exlusive worldwide license from Bayer Healthcare (Berlin, Germany) to an extensive Alpha7 patent estate.
|
